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. decimal separator 
< less than 
°C degree Celsius 
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µm micrometers 
AAT alpha-1 antitrypsin  
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COPD chronic obstructive pulmonary disease 
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et al. and others 
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Chronic obstructive pulmonary disease (COPD) is an incurable lung disease in 
which functional lung tissue, important for gas exchange, is lost (emphysema). 
Wnt/β-catenin signaling, crucial during lung repair, is reduced in COPD and 
pharmacological activation of the pathway in vivo as well as in ex vivo preclinical 
models, attenuates disease markers. The aim of this study was to identify a safe 
pharmaceutical compound able to activate Wnt/β-catenin signaling and assess its 
potential to induce lung repair in emphysema. 
We screened 1216 FDA-approved chemicals for Wnt/β-catenin signaling 
activation, using a cell-based Wnt reporter luciferase system. We further studied 
the regeneration potential of the approved drugs using a murine adult epithelial cell 
derived lung organoid assay and an in vivo model of lung emphysema. 
With the drug screen and further confirmatory assays we identify amlexanox as a 
new FDA-approved compound which can activate Wnt/β-catenin signaling. Using 
murine primary adult epithelial cell derived lung organoids, we show that 
amlexanox is able to initiate lung repair, demonstrated by increases in organoid 
formation capacity. In both cases the treatment effect could be reversed by 
pharmacological Wnt inhibition, confirming the Wnt-dependent mechanism of 
action of amlexanox. In vivo, mouse lung function, measured by dynamic 
compliance, was improved after 7 days of 50 mg/kg amlexanox administration. 
Gene expression analysis of important alveolar repair as well as disease markers, 
fibroblast growth factor 7 (Fgf7), hepatocyte growth factor (Hgf), ADAM 
metallopeptidase with thrombospondin type 1 motif 4 (Adamts4) and elastin (Eln), 




treatment. These data indicate that amlexanox may be useful for the regenerative 







Chronic diseases, also defined as non-communicable diseases (NCDs), are the 
leading cause of ill health in the world, likely to be of long duration and responsible 
for 71% of global and 80% of premature deaths (Bennett et al., 2018). The four 
major NCDs are cardiovascular diseases, cancers, diabetes and chronic 
obstructive pulmonary disease (COPD). 
In 2011, United Nations countries agreed on in nine global NCDs targets across a 
range of risk factors linked to lifestyle and demographic changes, such as tobacco 
use, physical inactivity, excessive alcohol consumption, unhealthy diets and air 
pollution. The World Health Organization (WHO) developed a Global Action plan 
to be implemented at high coverage levels with the aim of reducing NCDs burden 
and securing sustainable development in all countries. Ultimately, for reducing 
mortality from NCDs novel strategies for prevention, early detection and effective 
treatment options are needed (Heller et al., 2019). 
In parallel, the Global Alliance against Chronic Respiratory Diseases (GARD), an 
alliance of volunteer organizations, institutions and agencies, works globally 
towards improving lung health, acting according to local needs, both in disease 
prevention and control (Bousquet, Dahl & Khaltaev, 2007).  
Chronic lung diseases include asthma, pulmonary hypertension, occupational lung 
diseases, respiratory allergies, and COPD, and are the major responsible causes 





Figure 1.1. Different predicted lung function trajectories through the human life 
(Agusti & Faner, 2019; Agusti et al., 2019). In all trajectories there are three main 
phases: growth phase, where the lung is still under development, plateau phase, 
corresponding to the early adulthood, and decline phase, associated with lung 
ageing. “Catch-up” refers to evidenced recovery cases. Schematic adapted from 
the Fletcher-Peto diagram (Fletcher & Peto, 1977). 
 
The focus of this thesis is the development of effective therapies for COPD, using 
relevant preclinical disease models and targeting underlying mechanisms of 
aberrant lung tissue repair, namely dysregulated Wnt/β-catenin signaling. 
 
1.1. Chronic obstructive pulmonary disease 
Chronic obstructive pulmonary disease (COPD) was considered for a long time a 
single self-inflicted lung disease, caused by tobacco smoking, characterized by an 
inflammatory response damaging the airways (Figure 1.2.) (Agusti & Hogg, 2019). 
Current knowledge of COPD considers it a result of multiple long-term, dynamic, 
and cumulative gene–environment interactions, which shape the development, 
maintenance, and function of the lung, as well as of other organs, through complex 




a clinical syndrome which manifests as a heterogeneous lung disease, comprising 
various disorders of different origins, resulting in a partly reversible airflow limitation 
to which there is no curative treatment (Celli & Wedzicha, 2019). 
 
 
Figure 1.2. Human airway tree. A) scheme of the hierarchy of the airways divided 
into conducting airways and acinar or respiratory airways where gas exchange 
occur and B) scanning electron micrograph of a human section of the lung showing 
the characteristic fractal geometry which allows increased surface area for gas 
exchange within a confined space (Weibel, 2013). 
 
COPD is characterized by chronic respiratory symptoms, caused by structural 
pulmonary abnormalities, such as airways disease or emphysema (the destruction 
of alveolar airspaces) leading to lung function impairment (Celli & Wedzicha, 2019). 
Importantly, the understanding of COPD over the past decades has improved 
significantly. Each year, more people die with COPD, rather than from COPD 




practice involving prevention, early diagnosis and treatment of COPD that need to 
be met (Agusti, 2019). 
In 1997, the Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) 
was founded to raise awareness of COPD and improve both disease prevention 
and treatment. In 2001, the GOLD organization established a classification for the 
diagnosis of COPD, in order to divide patients into different categories according 
to airflow limitation severity. This classification is since then the basis for diagnosis 
and considers the ratio of two measurements obtained on pulmonary function test 
(spirometry). One is the patient’s forced expiratory volume in one second (FEV1), 
which measures the air volume a person can first exhale after a forced breath 
during the first second. The second is the forced vital capacity (FVC), the total 
volume of air exhaled after a full inspiration (Rodriguez-Roisin et al., 2017). COPD 
is diagnosed when the ratio FEV1/FVC is less than 0,70. FEV1 is reduced in COPD 
due to air trapping, thus the ratio FEV1/FVC is also reduced. 
As patients struggle for breath, COPD has a significant impact on the quality of life. 
This creates a great burden socially and economically, for the population who 
suffers from COPD, health care providers and governments (Quaderi & Hurst, 
2018). 
 
1.1.1. Epidemiology of COPD 
Since 2016, COPD is the third leading cause of death worldwide, being the top 
cause of death among respiratory diseases (Figure 1.3.). More than 3 million 




number is estimated to increase to 6,9% by 2060 (World Health Organization 
2018). 
 
Figure 1.3. Top 10 global causes of death. Respiratory diseases are highlighted 
in red. Data retrieved from official numbers provided by the World Health 
Organization (WHO, 2018). 
 
Although the number of COPD deaths has been either increasing or stabilizing, 
COPD mortality rates are declining in the majority of countries. On one hand due 
to improvements in COPD management, and on the other hand due to population 
growth and ageing (Lortet-Tieulent, Soerjomataram, Lopez-Campos, Ancochea, 
Coebergh & Soriano, 2019). COPD world prevalence is of 251 million cases (World 
Health Organization 2018). In the Rotterdam Study, a prospective cohort study 
encompassing 14926 participants ongoing since 1990, the overall incidence rate 
was approximately 9/1000 person-years (Terzikhan, Verhamme, Hofman, Stricker, 
Brusselle & Lahousse, 2016). 
The main risk factors of COPD are tobacco smoke and age, but also include other 




infections, socioeconomic status, comorbidities, clinical history during lung growth 
and development (GOLD, 2019). 
Tobacco smoke is the biggest risk factor of COPD in high- and middle-income 
countries. Meanwhile in low-income countries the main risk factor for COPD is 
exposure to indoor air pollution, such as the use of biomass fuels for cooking and 
heating (World Health Organization 2018). Furthermore, occupational exposures 
and outdoor air pollution also contribute to the pathogenesis of COPD. 
The observations that only a proportion of individuals smoking develop COPD, and 
that around 25% of COPD patients never smoked, supports that genetic as well as 
epigenetic factors have an impact in disease onset (Kohansal, Martinez-Camblor, 
Agusti, Buist, Mannino & Soriano, 2009; Salvi & Barnes, 2009).  
Hereditary deficiency of alpha-1 antitrypsin (AAT) is the major genetic susceptibility 
risk for COPD. Individuals with severe AAT deficiency (AATD) have an earlier 
onset of COPD, when compared to other patients, which often appears to not 
correspond to individual smoking history (Cazzola, Stolz, Rogliani & Matera, 2020). 
AAT is a protein encoded by the gene SERPINA1 in humans, responsible for anti-
protease activity. The protein targets include elastase, produced mainly by 
neutrophils, but also plasmin, thrombin, trypsin, chymotrypsin and plasminogen 
activator (Cohen, 1975). AAT is mainly synthesized in the liver, within the 
hepatocytes, in the intestine, pulmonary alveolar cells, neutrophils, macrophages, 
and cornea and is the most prevalent protease inhibitor in the human serum 
(Fagerberg et al., 2014; Strnad, McElvaney & Lomas, 2020). While proteases play 
important roles in the body, such as modulation of inflammation caused by host 




tissue homeostasis. The existence of efficient endogenous control mechanisms 
able to dampen excessive protease activity is essential for the resolution of 
inflammation. Although AAT has a broad-spectrum of anti-inflammatory, 
immunomodulatory, anti-infective and tissue-repair action, its main function is to 
protect sensitive lung tissue from proteolytic damage (Jonigk et al., 2013). AATD 
is an autosomal co-dominant condition, predisposing for the development of 
different disease phenotypes, depending on whether they occur due to a deficient 
variant, with impaired activity, or lack of protein production (null alleles). Persons 
with normal circulating levels of AAT carry two copies of the wild-type M allele of 
SERPINA1. Point mutations can lead to two phenotypic scenarios: a toxic “gain of 
function”, due to retention of AAT in the liver, causing liver disease, or a “loss of 
function”, responsible for lack of circulating proteinase inhibitor, predisposing to 
early-onset of emphysema. In 95% of the severe cases, AAT deficiency results 
from a homozygous substitution of a single amino acid, Glu342Lys, encoded by 
the allele Z. The most common allele causing mild AATD, the S allele, encodes an 
amino acid replacement, Glu264Val. Patients carrying loss of function alleles, or 
having the genotypic combinations ZZ, ZNull, or NullNull need periodic monitoring 
as they are at bigger risk of developing lung emphysema. Heterozygotes patients 
with the MZ and SZ genotypes who smoke need to be closely monitored, since 
they have a significant increased risk, as compared with general MM allele carriers, 
of developing lung disease (Strnad, McElvaney & Lomas, 2020). 
In a genome-wide association study, 279 genetic variants were associated with 
lung function signals. New signals implicating integrin subunit alpha V (ITGAV) and 
growth differentiation factor 5 (GDF5), as well as transforming growth factor beta 




support for the importance of elastic fiber pathways in COPD, which are known to 
be aberrant or diminished in patients with lung emphysema (Shrine et al., 2019). 
In an epigenome-wide association study, 28 differentially methylated sites 
associated with respiratory function and COPD. Functional analysis of the 
differentially methylated genes showed these were involved in alternative splicing, 
JAK-STAT signaling and axon guidance. Methylation status of 7 genes: suppressor 
of cytokine signaling 3 (SOCS3), strawberry notch homolog 2 (SBNO2), ral 
guanine nucleotide dissociation stimulator (RALGDS), islet cell autoantigen 1 
(ICA1), mitotic deacetylase associated SANT domain protein (ELMSAN1), ATP 
binding cassette subfamily A member 1 (ABCA1) and jade family PHD finger 1 
(JADE1); provided discriminatory power for COPD prediction (Bermingham et al., 
2019). Of note, JADE1 has been described to inhibit Wnt/β-catenin signaling, 
through ubiquitylation of both phosphorylated and non-phosphorylated β-catenin 
(Chitalia et al., 2008). 
 
1.1.2. Pathology, pathogenesis and pathophysiology of COPD 
COPD includes patients with widely varying clinical phenotypes and pathogenic 
mechanisms, which evolve according to different natural and individual histories 
(Agusti & Faner, 2018). Generally, the main pathological changes of COPD occur 
in the airways, lung parenchyma (the collection of small structures that pack an 
enormous surface area for gas exchange) and in the pulmonary vasculature (Suki, 
Stamenovic & Hubmayr, 2011). In turn, these are a consequence of a misbalanced 
proteolytic as well as anti-proteolytic activity, increased inflammatory response, 




decreasing cell proliferation and repair (Hadzic, Wu, Avdeev, Weissmann, 
Schermuly & Kosanovic, 2020) (Figure 1.4.). 
The epithelium is the first responder to environmental stimuli. Changes in the 
epithelial cell layer occur by an initial stimuli and further aggravate through a spiral 
of complications (Randell, 2006). Toxic gases and particles induce tissue damage 
either by increasing oxidative stress, or by initiating an inflammatory response. 
Airflow limitation in COPD is due to airway remodeling, wall thickness, and mucous 
production as a result of the infiltration of immune cells, such as neutrophils, 
macrophages, and lymphocytes, in the lung tissue. An immune response to either 
foreign antigens (such as commensal organisms or pathogens) or self-antigens 
(such as elastin), can contribute to the pathogenesis and aggravation of COPD 
(Wen, Krauss-Etschmann, Petersen & Yu, 2018). Progressive narrowing, and 
destruction of terminal airways is followed by microvascular abnormalities which 
contribute to emphysema, the degradation of matrix proteins in the distal parts of 
the lung (Higham, Quinn, Cancado & Singh, 2019). 
 
Figure 1.4. Summary of mechanisms involved in the pathogenesis of COPD 




1.1.3. Treatment of COPD 
As previously described, COPD is both a complex and heterogeneous disease. 
Complex because many components of the disease have no linear dynamic 
interactions, and heterogeneous because not every component is present in all 
patients, at all stages (Agusti, 2014). 
In general, the main goals of current available therapies for COPD are limited to 
reducing symptoms and risk of disease progression (GOLD, 2019). Targets for 
pharmacological treatments include airway smooth muscle contraction, 
inflammation, mucus production, alpha-1-antitrypsin deficiency and respiratory 
infection (Kerstjens, Upham & Yang, 2019). The classes of drugs used for the 
treatment of COPD include bronchodilators, anti-inflammatory, anti-infective and 
mucoregulator agents (Singh et al., 2019). 
To facilitate pharmacological management, the GOLD guidelines from 2017 
introduced a new refined strategy recommending an ABCD assessment for patient 
grouping based on symptoms and exacerbation risk (Rodriguez-Roisin et al., 
2017). Thus, pharmacological therapy of COPD is a patient-specific approach, 
individualized according to patient’s symptoms, airflow limitation, exacerbations 
and tolerance to therapy’s side effects. Bronchodilators target airway smooth 
muscle cells, allowing the airways to relax and become larger, improving patients 
breathing. The three major types of bronchodilators are: β2-agonists, 
anticholinergics and xanthines. Within β2-agonists and anticholinergics there are 
still two different classes based on their effect duration: short-acting (SABA and 
SAMA) and long-acting bronchodilators (LABA and LAMA) (Meek, Lareau, Fahy & 




combination. Anti-inflammatory drugs aim at reducing inflammation, preventing 
and treating exacerbations. These include corticosteroids and phosphodiesterase-
4 (PDE-4) inhibitors. Inhaled corticosteroids (ICS) are more commonly used in 
combination with a bronchodilator and treatment benefit can be measured by 
neutrophil blood count. For patients with prior history of hospitalization for an acute 
exacerbation, PDE-4 inhibitors have greater beneficial effects. Anti-infective 
agents such as vaccines, macrolides and antibiotics reduce the frequency of 
COPD exacerbations either through infection prevention or via immune system 
modulation. Finally, mucoregulators promote drainage of mucus from the lungs, 
reduce exacerbations and improve health status. 
Lung transplantation is the only curative treatment option for patients with COPD. 
However, organ availability, patient’s eligibility (such as advanced age or presence 
of other significant comorbidities), as well as tissue rejection and other associated 
complications make lung transplantation an unreliable treatment for most cases 
(Siddiqui & Diamond, 2018). Other surgeries which aim at lung volume reduction 
(LVRS), or removal of damaged tissue (e.g. bullectomy), are effective, but for a 
restricted number of patients and for short-term (Martinez & Chang, 2005; Meek, 
Lareau, Fahy & Austergard, 2019).  
 
1.2. Wnt signaling 
Wnt signaling is crucial for cell proliferation, differentiation and migration, but also 
important during organ development, maintenance, injury, aging processes and 




Wnts are a family of secreted glycoproteins which mediate cell to cell 
communication, either acting on neighboring cells or across a short distance 
(Skronska-Wasek, Gosens, Konigshoff & Baarsma, 2018; Wiese, Nusse & van 
Amerongen, 2018; Yeganeh et al., 2013). Wnt proteins are highly hydrophobic and 
show limited diffusion in the aqueous extracellular environment. Wnts regulate 
different signaling pathways which can be divided by β-catenin or β-catenin 
independent (Figure 1.5.). Focusing on the first signaling pathway, β-catenin is a 
transcriptional co-activator downstream effector of Wnt signalling in activated cells. 
In the absence of Wnts, the destruction complex formed by Axin, adenomatous 
polyposis coli (APC), glycogen synthase kinase-3 (GSK-3β) and casein kinase 1 
(CK1), is allocated in the cytoplasm, where it binds, phosphorylates, and 
ubiquitinates β-catenin through the E3-ubiquitin ligase β-TrCP before proteosomal 
degradation. In the presence of Wnts, these bind to Frizzled/ lipoprotein receptor-
related protein (LRP) heterodimeric receptor complexes, whereas the intact 
destruction complex associates with phosphorylated LRP. After this, the 
destruction complex captures and phosphorylates β-catenin, however 
ubiquitination is blocked. Thus, β-catenin stabilizes, accumulates and translocates 
to the nucleus. Next, β-catenin associates with T-cell factor/lymphoid enhancer-
binding factors (TCF/LEF) transcription factors for target gene transcription, such 




Figure 1.5. Schematic summary of the Wnt signaling pathway (Skronska-Wasek, 
Gosens, Konigshoff & Baarsma, 2018). 
 
1.2.1. Wnt signaling in lung development, injury and repair 
The human lung has three main developmental phases. The first, embryonic 
phase, goes from around weeks 4 to 7 of the embryonic stage, the second, fetal 
phase, goes from weeks 5 to 17 of embryonic stage and the third, the postnatal, 
goes from birth (~38 weeks of embryonic stage) to 3 years of age (Schittny, 2017). 
The lung grows approximately until the ages of 10 and 12 years and further 
matures until the age of 20 for females and 25 for males (Brandsma, de Vries, 
Costa, Woldhuis, Konigshoff & Timens, 2017). Lung development starts centrally 
at the conducting airways and progresses into the periphery by the formation and 
enlargement of the gas exchange area, and microvascular maturation. Very 
specific differential expression of factors from different signaling pathways, such 
as Wnt, fibroblast growth factors (FGF), bone morphogenic protein (BMP), and 
transforming growth factor beta (TGF-β), provide instructions for branching 




shown to lead to lung agenesis (Goss et al., 2009; Harris-Johnson, Domyan, 
Vezina & Sun, 2009; Yin et al., 2008). After lung maturation, lung function 
progressively declines with age as a consequence of lung changes both in 
structure and physiology, as presented in the beginning of this section. The 
alveolar compartment of the lung is indispensable for life, so there is great interest 
in understanding its cellular composition and how to regenerate the thin interface 
for gas exchange after injury. Different studies suggest the lung remains largely 
quiescent after development, but that upon injury, multiple cell types are able to 
proliferate and restore the lung structure (Butler, Loring, Patz, Tsuda, Yablonskiy 
& Mentzer, 2012; Liu et al., 2019; Nabhan, Brownfield, Harbury, Krasnow & Desai, 
2018; Zacharias et al., 2018). A wide-range of cell lineages can be stimulated to 
proliferate, de- or re-differentiate, and even modify their phenotype to repair an 
injured lung area. (Zepp & Morrisey, 2019). Wnt proteins are crucial during these 
processes as they are responsible for regulating stem cell maintenance and cell 
self-renewal (Figure 1.6.). 
Figure 1.6. Schematic model of alveolar cell niche during homeostasis and injury 
(Nabhan, Brownfield, Harbury, Krasnow & Desai, 2018). Alveolar type 1 (AT1) and 




1.2.2. Wnt signaling in COPD 
In COPD, an exhausted and defective alveolar epithelial repair has been 
associated with recurring toxic exposure and Wnt signaling dysregulation (Basil et 
al., 2020). We and others have shown it to be decreased in COPD (Baarsma et al., 
2017; Jiang et al., 2016; Kneidinger et al., 2011; Skronska-Wasek et al., 2017; Uhl 
et al., 2015; Wang et al., 2011). The decrease in Wnt signaling has been 
associated with alveolar type II cells, adult lung alveolar stem cells, which display 
inactive Wnt/ β-catenin signaling in COPD (Figure 1.7.). 
Figure 1.7. Immunohistochemistry staining of type II alveolar epithelial cells, 
demarked by SPC in red, and β-catenin, in grey, of lung sections obtained from 
non-diseased patients, donor, and COPD patients (Kneidinger et al., 2011). 
 
We have also previously demonstrated that Wnt/β-catenin signaling is a promising 




using precision-cut lung slices derived from COPD patients (Figure 1.8.) 
(Kneidinger et al., 2011; Uhl et al., 2015). 
Figure 1.8. Hematoxylin and eosin staining of mice lung sections showing that 
lithium chloride (LiCl) in vivo administration attenuates emphysema changes in 
mice challenged with elastase (Kneidinger et al., 2011). 
 
Wnt activation has been previously achieved experimentally using lithium chloride 
(LiCl) and CHIR99021, two well-known GSK-3β inhibitors. However, there are 
toxicity concerns in regards to their systemic use in humans (De Meyer et al., 2011; 
Uhl et al., 2015). 
 
1.2.3. Wnt signaling modulation 
As briefly mentioned above, it is possible to pharmacologically target the Wnt 
signaling pathway (Figure 1.9.). The interaction between different Wnt signaling 
components can be interrupted, resulting in either inhibition or activation of the 
pathway. For instance, the interaction of transcription factors TCF/LEF with β-
catenin can be disrupted by various compounds including, PKF115-584 and 





Figure 1.9. Small molecule inhibitors of different Wnt/β signalling pathway 
components (Tran & Zheng, 2017). 
 
There is a broad interest in modulating Wnt signaling therapeutically, not only for 
COPD, but also for diseases like cancer, osteoporosis, Parkinson’s disease and 
lung fibrosis (Baarsma & Konigshoff, 2017; Zimmerman, Moon & Chien, 2012). 
However, Wnt remains challenging as a target due to its complexity both in terms 
of multiple players and in terms of crosstalk with other signaling pathways, such as 
Hedgehog, Notch and TGF-β (Borggrefe, Lauth, Zwijsen, Huylebroeck, Oswald & 
Giaimo, 2016). In addition, modulation of Wnt through activation or inhibition of 
different protein pathways can prompt unique responses in different cell types 
(Anastas & Moon, 2013). Like during organ development, a strongly regulated and 
spatio-temporal control of gene expression is necessary for the development of 








2. Hypothesis and aims 
There is evidence that the lung has a regeneration potential after development. In 
COPD, endogenous repair capacity of the human diseased lung is diminished, 
however there are studies indicating that the remaining lung tissue is capable of 
responding to novel treatment options, such as Wnt/β-catenin activation. 
The hypothesis of this PhD thesis is that Wnt/β-catenin exogenous activation can 
regenerate emphysematous lung tissue and that this can be achieved by 
repurposing FDA-approved compounds which can activate the Wnt pathway. 
Thus, the main aim of this study was to identify a safe and effective compound for 
Wnt/β-catenin signaling activation in the lung which is able to induce lung repair in 
the context of lung emphysema. 
We defined the following subaims: 
1) to develop a robust and reliable cell-based high-throughput compound screen, 
using a luciferase Wnt reporter cell line; 
2) to identify drug candidates able to activate Wnt/β-catenin signaling; 
3) to select drugs based on their protein target prediction and confirmatory assays; 
4) to validate them in a relevant preclinical model of lung tissue regeneration; 









3. Materials and methods 
3.1. Cell culture 
Leading Light Wnt Reporter cells (Enzo Life Sciences) and NIH/3T3 (ATCC CRL-
1658, ATCC) cells were cultured in high glucose Dulbecco's Modified Eagle 
Medium, DMEM (Gibco), supplemented with 4 mM L-alanyl-L-glutamine dipeptide 
(Gibco), 10% (v/v) fetal bovine serum, FBS (PAN-Biotech) and 100 U/ml penicillin 
and streptomycin (Gibco). For all experiments using NIH/3T3 and Leading Light 
Wnt Reporter cells, well plates were coated with poly-L-lysine (Sigma-Aldrich). 
Briefly, culture surfaces were aseptically covered with poly-l-lysine for 5 min., 
solution was aspirated and plates were thoroughly rinsed with 1x sterile phosphate 
buffered saline solution, PBS pH 7.4 (Thermo Fisher Scientific). Wells were 
allowed to dry at least for 2 h before introducing cells and medium. MLg (ATCC 
CCL206, ATCC) cells were cultured in DMEM/Ham’s F12 media (Gibco) 
supplemented with 10% (v/v) FBS, 100 U/ml penicillin and streptomycin. All cells 
were expanded in T-75 cm2 flasks (Thermo Fisher Scientific) made from 
polystyrene (PS) and grown at 37°C with 5% CO2 in humidified conditions, using a 
CO2 cell Incubator BBD6620 (Thermo Fisher Scientific). For cell detachment, cells 
were rinsed with 1x PBS and incubated with 1 ml of 0.25 % Trypsin-EDTA for 5 
minutes at 37°C. Trypsin activity was neutralized with 10 ml of 10% FBS growth 
media. Cell suspension was transferred to a 50 ml conical tube (BD Bioscience) 
and centrifuged for 5 minutes at 300 g and room temperature, using a centrifuge 
Rotina 420R (Hettich). Next, supernatant was carefully aspirated. For 
cryopreservation, 1 x 106 cells were suspended in freezing medium composed by 
10% (v/v) dimethyl sulfoxide, DMSO (Carl Roth), 40% (v/v) media and 50% (v/v)  
FBS, and kept in a Liquid nitrogen cell tank BioSafe 420SC (Cryotherm). Cell 
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numbers were calculated using a Neubauer chamber, trypan blue 0.4% solution 
(Sigma-Aldrich) at a 1:2 dilution and the following formula: cell concentration 
(number of cells/ml of cell suspension) = (number of cells counted x 10.000) / 
number of squares counted. For all liquid pipetted volumes, either sterile 
measuring pipettes (Greiner bio-one) of single use (5 ml, 10 ml, 25 ml, 50 ml) were 
used with the help of PIPETGIRL (Integra) or filter tips (Biozym Scientific) were 
used (10µl, 100µ, 200µl and 1000µl) with fixed volume, single channel Research 
Plus pipettors (Eppendorf). To achieve sterile conditions, tissue culture was 
performed under a laminar flow hood Herasafe KS (Thermo Fisher Scientific). 
 
3.2. Reagents 
CHIR99021 (Tocris), amlexanox (Cayman Chemical), nabumetone, 
phenazopyridine hydrochloride, tolnaftate (Santa Cruz Biotechnology) and 
tiaprofenic acid (Sigma-Aldrich) were all dissolved in DMSO to a stock 
concentration of 20mM. PKF115-584 and iCRT14 (Tocris) were dissolved in 
DMSO to a stock concentration of 1 mM and 75 mM respectively. Lithium cloride 
(Sigma-Aldrich) was dissolved in culture media to a stock solution of 2 M. Reagents 
were stored as stock solution at -20 °C, using a freezer MediLine LGex 410 
(Liebherr). 
 
3.3. High-throughput small compound screen 
For the compound screen, Leading Light Wnt Reporter Cell Line stably expressing 
firefly luciferase under the control of T-cell factor/lymphoid enhancer-binding 




media were dispensed in tissue culture treated and sterilized white opaque 384-
well plates (PerkinElmer) and allowed to adhere for 24 hours at 37°C in 5% CO2 in 
humidified conditions. Cells were serum starved with 0.1% (v/v) FBS media for 24 
hours to allow for cell synchronization prior to treatment. Cells were afterwards 
treated for 24 hours with 1,216 10 µM of compounds belonging to the Prestwick 
Chemical Library (Prestwick chemical) in 0.1% (v/v) FBS-supplemented medium, 
without replicates. 1% (v/v) DMSO, and 10 µM CHIR99021 were used as negative 
and positive controls, respectively, each dispensed in the first and last well plate 
columns (replicates of 16 wells). Media was removed and 25 µl of Bright-Glo 
Luciferase Assay System (Promega) was added to each well. Luminescence was 
measured using an EnVision 2102 Multilabel Reader (PerkinElmer). The quality 
and robustness of the assay was calculated using the Z′ factor and the signal 
window (Zhang, Chung & Oldenburg, 1999). Hit threshold was set above plate 
average signal of the compounds plus 3 times the standard deviation. The 
compound library treatment was distributed in four different experiments. For this, 
same passage number of cells was used to guaranty consistency between cell 
batches. 
 
3.4. Drug selection 
Computational exclusion of potential false positives was performed by chemical 
structure comparison of compounds active in both the high-throughput small 
compound screen and in multiple assays, publically available in PubChem and 
ChemBank databases. c (Liu & Campillos, 2014). The activity of compounds in the 
PubChem bioassays was taken as provided by the database. After drug exclusion, 
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based on compound promiscuity, drug targets were predicted with high confidence 
(>50% precision), using the software HitPick (Liu, Vogt, Haque & Campillos, 2013). 
Final candidate drugs were selected based on the number 1) of hits of a Pubmed 
literature search composed by: “predicted target” + “COPD” or “predicted target” + 
“Wnt”; and 2) of predicted targets belonging to the gene ontology terms “epithelial 
cell proliferation” (GO:0050673) and “regulation of inflammatory response” 
(GO:0050727), relevant in COPD. 
 
3.5. Luciferase reporter assay 
6 x 104 Leading Light Wnt Reporter cells were seeded in each well of a 48 well 
plate (TPP Techno Plastic Products), flat bottom made from polystyrene (PS), 
0.875 cm2 growth area, 10.6 mm diameter, suspended in 250µl of 10% (v/v) FBS 
supplemented phenol red free media. Cells were allowed to adhere for 24 hours at 
37°C in 5% CO2 in humidified conditions. Next, cells were serum starved with 0.1% 
(v/v) FBS media for 24 hours to allow for cell synchronization prior to treatment. 
Cells were afterwards treated for 24 hours with 0.5, 1, 5 and 10 µM of either 
amlexanox, phenazopyridine hydrochloride, tolnaftate, nabumetone and 
tiaprofenic acid alone or in combination with 1 µM PKF115-584, a Wnt inhibitor. 
0.05% (v/v) DMSO was used as negative control, and 1 µM CHIR99021 and 10mM 
LiCl, two Wnt inducers, were used as positive controls. Plates were stored at -80 
°C turned upside down, in a freezer U570 HEF (New Brunswick) until further 
processing. Cells were then lysed with 65 µl of Glo Lysis Buffer (Promega) for 30 
minutes at room temperature in an orbital shaker Duomax 1030 (Heidolph). After 




microplate (Corning), flat bottom, untreated and made from PS. Luciferase activity 
was determined using the software Tristar MicroWin 2000, version 4.41 (Berthold 
Technologies), a luminescence microplate reader (Berthold Technologies) with an 
automatic injection and shaking system, which dispensed 100 µl of Bright-Glo 
Luciferase Assay System to the lysates and shook plates before each value 
acquisition. The measured values were analyzed with WinGlow Software (Berthold 
Technologies) and normalized to control. Quantifications were based on at least 3 
independent experiments, each condition performed in triplicates. 
 
3.6. Cell viability assay 
Cell viability analysis was performed using CellTiter-Glo (Promega) according to 
the manufacturer's instructions, in NIH/3T3 cells. 2.5 x 104 cells were seeded in 
each well of a 96 well plate (TPP Techno Plastic Products), flat bottom, made from 
PS, with a 0.322 cm2 growth area, 6.40 mm in 100 µl 10% (v/v) FBS growth media. 
The assay was performed after 24h of compound treatment and measurements 
were done in triplicates using a luminescence plate reader. The measured values 
were analyzed with WinGlow Software and normalized to control. Quantifications 




Eight to twelve weeks old pathogen-free wild type mice weighing 20 to 22 g were 
used in this study. C57BL/6N mice were purchased from Charles River 
Laboratories (Sulzfeld, Germany) and C57BL/6J mice from The Jackson 
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Laboratory (Maine, USA). Animals were housed in rooms maintained at constant 
temperature and humidity, with a 12 hour light cycle, and were allowed food and 
water ad libitum. Experiments were conducted under strict governmental and 
international guidelines, according to the regulatory guidelines of University of 
Colorado Institutional Animal Care and Use Committee. Animal studies are 
reported in compliance with the ARRIVE guidelines (Kilkenny, Browne, Cuthill, 
Emerson, Altman & Group, 2010). 
 
3.8. Mouse lung epithelial cell isolation 
Lung epithelial cells were isolated as previously described (Messier, Mason & 
Kosmider, 2012; Mutze, Vierkotten, Milosevic, Eickelberg & Konigshoff, 2015; Ng-
Blichfeldt et al., 2018) with slight modifications. C57BL/6N female mice were 
anaesthetized with a mixture of 300 mg/kg body weight ketamine (Bela-pharm) and 
100 mg/kg body weight xylazine (cp-pharma), sacrificed, through exsanguination 
by cutting the vena cava, and lungs were flushed with PBS. Mouse lungs were 
intratracheally inflated with dispase (BD Bioscience) followed by 300 µl instillation 
of 1% (w/v) low gelling temperature agarose (A9414, Sigma Aldrich). Lungs were 
harvested, minced and filtered through 100 µm, 20 µm and 10 μm nylon meshes 
(Sefar) with the help of surgical scissors and forceps (Fine Science Tools). White 
blood cells were depleted with CD45 and epithelial cells were selected using 
CD326 (EpCAM) magnetic beads respectively (130–052-301, 130–105-958, 
Miltenyi Biotec), according to manufacturer’s instructions, using manual separators 
for magnetic cell isolation (Miltenyi Biotec). EpCAM+ cells were resuspended in 
DMEM containing 2 mM L-alanyl-L-glutamine dipeptide (Gibco), 100 U/ml penicillin 




HEPES (Thermo Fisher Scientific) and left on ice until further use. Primary mouse 
lung epithelial cells were either used in the organoid assay or seeded in 6 well 
plates (TPP Techno Plastic Products). 
 
3.9. Murine lung organoid culture 
Organoids were cultured as previously described (Barkauskas et al., 2013; Ng-
Blichfeldt et al., 2018) with some modifications. Briefly, MLg mouse lung fibroblasts 
were proliferation-inactivated by incubation in culture medium containing 10µg/ml 
mitomycin C (Merck) for 2 h, followed by 3 washes in warm PBS, and let to recover 
in culture media for at least 1 hour. 20,000 primary lung epithelial cells (EpCAM+ 
cells) suspended in 50 µl growth factor-reduced Matrigel (Corning) were diluted 1:1 
with 20,000 MLg cells in 50µl DMEM/F12 containing 10% (v/v) FBS and seeded 
into 24-well plate tissue culture treated transwells inserts (Corning) with 0.4 µm 
pore size, made from polyester (PET) membrane, growth area 0.3 cm² and 6.4 mm 
diameter. Cultures were maintained in DMEM/F12 containing 5% (v/v) FBS, 100 
U/ml penicillin and streptomycin, 2 mM L-alanyl-L-glutamine dipeptide (Gibco), 2.5 
µg/ml amphotericin B (Gibco), 1x insulin-transferrin-selenium (Gibco), 0.025 µg/ml 
recombinant human epidermal growth factor, EGF (Sigma), 0.1 µg/ml cholera toxin 
(Sigma-Aldrich), 30 µg/ml bovine pituitary extract (Sigma-Aldrich) and 0.01 µM of 
freshly added all-trans retinoic acid (Sigma-Aldrich) beneath the inserts. 10 µM Y-
27632 (Tocris) was added to the media for the first 48 hours of culture. Treatments 
were added to the organoid media from day 0 and in every culture media exchange. 
Media was refreshed every 2-3 days.  
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3.10. Organoid quantification 
Microscopy for organoid quantification at day 14 was performed using a 
microscope Axiovert 40 (Zeiss). Individual organoids from multi-layer Z-stacks, 
with a minimum size of 50 µm, were manually selected using the Fiji image 
processing package (Schindelin et al., 2012). The total number of organoids was 
then normalized to treatment control. 
 
3.11. Immunofluorescence 
Immunofluorescence staining of organoids was done as previously described (Ng-
Blichfeldt et al., 2018). Organoids were kept in well inserts and fixed at day 14 with 
ice-cold acetone-methanol mixed 1:1 (AppliChem) for 15 minutes at -20°C. Next, 
organoids were blocked with 5% (w/v) BSA (Sigma-Aldrich) dissolved in PBS, and 
further stored at 4°C. The following day, organoids were incubated with primary 
antibodies diluted in PBS with 0.1% (w/v) BSA and 0.1% (v/v) Triton X-100 solution 
(AppliChem) at 4°C. The next day, organoids were washed with PBS and 
incubated with secondary antibodies, diluted 1:200 at 4°C. Finally, on the third day 
cell nuclei were stained with 4′-6-diamidino-2-phenylindole, DAPI, (Roche) diluted 
1:1000 for 10 minutes. Antibodies and dilutions used were: E-Cadherin 1:200 
(610181, BD Bioscience), prosurfactant protein C 1:100 (AB3786, Millipore), 
acetylated alpha tubulin 1:2000 (ab24610, Abcam), donkey anti-mouse IgG 
conjugated with Alexa Fluor 647 1:200 (ab150107, Abcam), goat anti-mouse IgG 
conjugated with Alexa Fluor 568 1:200  (A11031, Invitrogen) and goat anti-rabbit 
IgG conjugated with Alexa Fluor 488 1:200 (ab150077, Abcam). 




or a microscope Axio Imager M2 (Zeiss). Images were processed using ImageJ 
(Schindelin, Rueden, Hiner & Eliceiri, 2015). 
 
3.12. Amlexanox preparation and in vivo administration 
Amlexanox was administered to C57BL/6J mice by oral gavage as previously 
described (Reilly et al., 2013). Amlexanox was first dissolved in 150 mM NaOH, to 
a final concentration of 20 mg/ml. The solution was further diluted using a 1:1 
mixture of water and 1.5 M tris(hydroxymethyl)-aminomethane hydrochloride, Tris-
HCl buffer pH 8.8, to achieve a final concentration of 10 mg/mL, which was further 
buffered to a pH of > 7.5 solution, to avoid amlexanox precipitation. Same solution 
without amlexanox was used as vehicle control. Mice were treated on a daily basis, 
from Day -1 (the day before of elastase instillation) to Day 6, in a preventive 
regimen, with either 25 or 50 mg/kg amlexanox. Mice were randomized and divided 
into the following groups: diseased controls (elastase), diseased treated mice 
(elastase plus amlexanox treatment). Experiments were performed twice, once 
with 25 mg/kg of amlexanox and once with 50 mg/kg, with 10 animals per group (5 
male and 5 female). 2 of the mice died before the end of the experiment, due to 
the lung injury, resulting in a final n of 9 for each of the amlexanox treatments 
groups. 
 
3.13. Elastase mouse model of emphysema  
Emphysema was induced as described previously (Kneidinger et al., 2011). 
Elastase is an enzyme known to induce destruction of lung tissue. The elastase-
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induced injury model is widely used to study emphysema and well documented 
(Wright, Cosio & Churg, 2008). Shortly, porcine pancreatic elastase (Sigma-
Aldrich) was dissolved in sterile PBS (Gibco) and applied orotracheally (4U/100g 
body weight in 80 μl PBS) in 3% isoflurane anaesthetized C57BL/6J mice. Animal 
health status and weights were closely monitored on a daily basis. 
 
3.14. Lung function measurement 
C57BL/6J mice were anaesthetized with ketamine-xylazine, tracheostomized, 
intubated and connected to a FlexiVent FX system (SCIREQ) (John-Schuster et 
al., 2014). Mice were ventilated with a tidal volume of 10 ml/kg at a frequency of 
150 breaths/minute to reach a mean lung volume similar to that of spontaneous 
breathing. Testing of lung mechanical properties including dynamic lung 
compliance and resistance was carried out by a software-generated script. 
Measurements were repeated four times per animal. The coefficient of 
determination (COD), a quality control parameter comparing the experimental 
signals and the lung function software models, was determined by the system. Only 
datasets with a coefficient higher than 0.95 were included in the analysis. Following 




To decrease unintentional bias, personnel was blinded to experimental groups 




blinding process, samples were randomly excluded so that sample sizes were the 
same between treatment groups during processing and analysis. 
 
3.16. RNA extraction, cDNA synthesis and quantitative real-time PCR 
Total RNA from cells was isolated using the peqGOLD Total RNA Kit (Peqlab), 
according to the manufacturer's instructions. Fresh lung tissue was snap frozen in 
liquid nitrogen, with the help of a nitrogen container (KGW Isotherm) and kept at 
−80 °C until further processing. Frozen tissue was pulverized using a TissueLyser 
II (Qiagen), 7 mm steel beads (Qiagen) in 2 ml safe-lock reaction tubes (Eppendorf) 
at a frequency of 25 s-1 for 1 minute. Total RNA from lung tissue homogenate was 
isolated using QIAzol (Qiagen) and purified with the peqGOLD Total RNA Kit 
(Peqlab), using a centrifuge Mikro 200 (Hettich). RNA was quantified using a 
NanoDrop 1000 (PeqLab). 1 μg of RNA in 20 μl RNase/DNase free water (Gibco) 
was denatured at 72 °C for 10 minutes in a Mastercycler nexus (Eppendorf). cDNA 
was synthesized by reverse transcription, using 2.5 U/µl M-MLV Reverse 
Transcriptase (Invitrogen), 1X First Strand Buffer (Invitrogen), 10 mM DTT 
(Invitrogen), 2.5µM random hexamers (Invitrogen), 0.5 mM of nucleotide (dNTP) 
mix (Thermo Scientfic), and 1 Unit/µl RNase inhibitor (Thermo Scientfic). 
Incubation at 20 °C for 10 min. was followed by an annealing cycle at 43 °C for 75 
min and an extension at 99 °C for 5 min and left at 4°C for cooling down, in a PCR 
reaction. cDNA was diluted 1:5 with water and stored at -20 °C. mRNA expression 
of target genes was compared with reference control hypoxanthine-guanine 
phosphoribosyltransferase (Hprt)-1, using SYBR Green (Roche) and a LC480 
Light Cycler (Roche). Primers were used at a final concentration of 500 nM with 
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the following sequences: Hprt forward 5’-CCTAAGATGAGCGCAAGTTGAA-3’, 
reverse 5’-CCACAGGACTAGAACACCTGCTAA-3’, Axin2 forward 5’- 
AGCAGAGGGACAGGAACCA-3’, reverse 5’-CTGAACCGATTCATGACCAC-3’, 
Lgr5 forward 5’-GCGTTCACGGGCCTTCACAG-3’, reverse 5’-
GGCATCTAGGCGCAGGGATTGA-3’, Fgf7 forward 5’-
AGGCTCAAGTTGCACGAGGC-3’, reverse 5’-
GCGGTTGCTCCTTGACTTTTGTT-3’ Hgf forward 5’-
TGCCTGTGCCTTGACTTAGCG-3’, reverse 5’-
CCGGGCTGAAAGAATCAAAGCA-3’, Adamts4 forward 5’-
AACCAAGCGCTTCGCTTCTCT-3’, reverse 5’-AGCTGCCATAACCGTCAGCA-3’, 
Eln forward 5’-GGCGTCTTGCTGATCCTCT-3’ reverse 5’-
ATAATAGACTCCACCGGGAACT-3’ Mmp12 forward 5’-
TGTACCCCACCTACAGATACCTTA-3’ reverse 5’-
CCATAGAGGGACTGAATGTTACGT-3’. The reaction conditions used for the 
qPCR were: initial denaturation for 5 min. at 95 °C, followed by 45 cycles of 
denaturation for 5 s. at 95 °C, annealing for 5 s. at 59 °C and elongation for 10s. at 
72 °C, followed by a cycle step for melting curve analysis to acquire the dissociation 
characteristics of double-stranded DNA, for 5 s. at 95 °C, 1 min. at 60 °C and a 
continuous acquisition from 60-95 °C, ending and a final cooling step at 4 °C. 
Relative transcript expression of a gene was calculated as difference between 





3.17. Statistical analysis 
Data were analyzed with GraphPad Prism 8.0. and presented as mean ± SD. n 
refers to number of independent experiments. The statistical tests used are stated 









4.1. Wnt/β-catenin luciferase reporter cell based screening identifies human 
approved drugs as Wnt activators 
To discover a pharmaceutical which could activate Wnt/β-catenin signaling, we 
screened 1216 clinical approved drugs by the European Medicine Agency (EMA), 
Food and Drug Administration (FDA) and other agencies, using a Wnt luciferase 
reporter cell line (Figure 4.1.). 
 
Figure 4.1. Cell-based Wnt/β-catenin reporter high-throughput drug screening. a) 
Phase-contrast image of Leading Light Wnt Reporter Cell Line used for the drug 
screen. b) Schematic of DNA construct stably expressed in the Leading Light Wnt 
Reporter Cell Line. The firefly luciferase reporter gene is under the control of a 
basal promoter element, TATA box, joined to tandem repeats of a proprietary and 
non-disclosed Wnt-responsive elements (TCF/LEF binding site). c) Experimental 
design of the drug screening. Leading Light Wnt Reporter Cell Line was seeded in 
384 well-plates, serum starved (0.1% FBS containing media) for 24 hours, and 
treated for another 24 hours with 10 µM of each compound, using the Prestwick 
chemical library, consisting of 1216 approved drugs. Luciferase assay was 
performed, luminescence values were analyzed and luciferase activity was 






The quality metrics for our high-throughput screen were determined by the Z′ factor 
and the signal window, which were calculated for the four different plates, run on 
different days (Figure 4.2.). The Z’-factor is a parameter that takes into account the 
signal means and standard deviations, being highly sensitive to data variability. 
The assay is accepted if this value is greater than 0.4 (Zhang, Chung & Oldenburg, 
1999). The signal window is used to estimate the uniformity and separation of the 
upper and lower signals of the assay. When this parameter is greater than 2, the 
assay is considered acceptable. As an outcome of our validation process, we 
accepted the results of all four plates, as both robust and reliable. 
 
Figure 4.2. High-throughput assay quality metrics, calculated for each assay plate. 
a) Z’ factor and b) signal window. 
 
We identified 16 drugs that increased β-catenin-dependent luciferase activity 
(Figure 4.3.). 12 drugs were in the Wnt inhibitory range of the assay, but were not 
further explored, as this was not within the aims of this project. 
The hit threshold for our assay was set above the mean signal of the general 
compound signal, shifted by three times the standard deviation, specific for each 




Figure 4.3. Luciferase assay results of the Wnt/β-catenin reporter high-throughput 
drug screening. Compound screen identified 16 Wnt/β-catenin/TCF/LEF 
activators. Hits Z-score was set as greater than the average signal of all 
compounds plus three times the standard deviation. White dots highlight the five 
selected candidate compounds: amlexanox, phenazopyridine hydrochloride, 
tolnaftate, nabumetone and tiaprofenic acid. 
 
For further analysis, we selected five candidate compounds from the 16 hits (Table 
4.1.). The selected compounds amlexanox, phenazopyridine hydrochloride, 
tolnaftate, nabumetone and tiaprofenic acid had different Wnt induction capacities 
in our drug screen. Furthermore, the candidate drugs have different chemical 
structures and belong to different therapeutic classes, except for phenazopyridine, 




Table 4.1. Candidate compound summary. 
 
The selection of the five drugs was based on a promiscuity analysis in ChemBank 
and PubChem databases and in the hit predicted protein targets (Figure 4.4.). 
From the 16 hits, 12 and 15 were previously tested in other assays and results are 
publicly available in the ChemBank and PubChem databases, respectively. 
Regarding the predicted protein targets of our hits, from the total 16 candidates, it 
was possible to identify predicted targets for 15 hits. These 15 hits to which it was 
possible to identify predicted protein targets, differed from the 15 hits with 






Figure 4.4. Venn diagram showing the overlap of hits to compounds tested in 
ChemBank and PubChem bioassay databases, as well as compounds with 
predicted targets. 
 
In detail, the promiscuity analysis took into account the activity information 
available in public screen repositories. For this, we calculated the ratio between 
the number of assays in which the hits were tested and the number of assays in 
which the hits were active (Table 4.2.) in comparison with our 16 hits. Tiaprofenic 
acid lacked bioassay activity information reported in the public sets. For 
amlexanox, no data regarding bioassay activity could be retrieved from the 
ChemBank database. 
 




For the prediction of each candidate protein target, we used the bioinformatic tool 
HitPick (Figure 4.5.). HitPick combines two methods for target prediction. One 
based on the compounds’ 2D molecular fingerprint which calculates a Tanimoto 
coefficient, accounting for the most similar compound from a database. The 
second, a Bayesian model, generates a ranked list of target predictions of known 
ligand–target interactions of the most similar compound. 
 
Figure 4.5. Schematic of HitPick protein target prediction strategy (Liu et al., 2013). 
 
With the predicted protein targets, we performed a literature Pubmed search using 
the keywords “Wnt” or “COPD” or the GO terms “epithelial cell proliferation” or 
“regulation of inflammatory response” (Table 4.3.). Amlexanox’s targets were the 
most associated with all four criteria. Predicted targets for phenazopyridine 
hydrochloride and tolnaftate were associated with “COPD” and “regulation of 
inflammatory responses”. Nabumetone and tiaprofenic acid targtes were both 
associated with “Wnt” or “COPD” and “regulation of inflammatory response”. 
According to this selection strategy, although all five compounds induced Wnt/β-







Table 4.3. Summary of literature search of the final five selected candidates drugs. 
 
4.2. Inhibition of β-catenin reduces Wnt dependent luciferase activity in 
amlexanox and phenazopyridine hydrochloride treated cells 
Next, we aimed at confirming the candidate drugs amlexanox, phenazopyridine 
hydrochloride, tolnaftate, nabumetone and tiaprofenic acid, selected in our primary 
screen. First, we wanted to validate that the identified drugs regulated specifically 
β-catenin signaling. To do so, we treated the Wnt reporter cells with four different 
concentrations of the candidate drugs alone or together with PKF115-584, a well-
known compound, inhibiting the T cell factor (TCF)–β-catenin complex 
(Lepourcelet et al., 2004). In all single compound treatments, there was a 
significant increase in luciferase activity, confirming the results of our drug screen. 
Wnt induction was achieved in all compound concentrations, except for the lower 
dose of tiaprofenic acid. Inhibition of β-catenin led to a significant decrease in 
luciferase activity only in amlexanox and phenazopyridine treatments (Figure 4.6.). 
For tolnaftate, nabumetone and tiaprofenic acid, there was also a decrease in 
luciferase activity, but not significant. At the same time, we observed that lithium 
chloride (LiCl), a classic inhibitor of GSK-3β and only patient-experienced drug 




reporter system, but had a lower luciferase activity induction compared to the 
candidate drugs. 
Figure 4.6. Luciferase assay in Leading Light Wnt Reporter Cell Line treated with 
0.5, 1, 5, or 10 µM of candidate compounds for 24 hours with or without 1µM 
PKF115-584, calphostin C, an antagonist of TCF/β-catenin complex. GSK-3β 
inhibitors, 1µM CHIR99021 and 10mM LiCl were used as positive controls. 
Luciferase activity was calculated relative to negative control (DMSO). n=3-10. 
One sample t-test to a hypothetical value of 1, *p<0.05, and One-way ANOVA, 
#p<0.05. Data is presented as mean ± SD of independent experiments. Control 
(DMSO), lithium chloride (LiCl), amlexanox (AML), phenazopyridine hydrochloride 
(PHE), tolnaftate (TOL), nabumetone (NAB) and tiaprofenic acid (TIA). 
 
Second, the five selected candidate hits were analyzed in a dose dependent 
manner with respect to their proliferative capacity, to rule out the possibility that the 
increase in luciferase activity was due to an increase in cell number (Figure 4.7.). 
We observed that there were no significant changes in the metabolic activity of the 
cells treated with the candidate drugs, measured by ATP levels, accounting both 
for proliferation and toxicity. Cell proliferation was only observed in the CHIR99021 
treated cells. Based on these results, we continued our investigation with the 






Figure 4.7. Metabolic activity of NIH/3T3 cells treated with 0.5, 1, 5, or 10 µM of 
candidate compounds for 24 hours was evaluated by ATP levels, measured with 
cell titer glo luminescent cell viability assay. 1 µM CHIR99021 was used as a 
positive control. Metabolic activity was calculated relative to negative control 
(DMSO). n=4. One sample t-test to a hypothetical value of 1, *p<0.05. Data is 
presented as mean ± SD of independent experiments. Control (DMSO), lithium 
chloride (LiCl), amlexanox (AML), phenazopyridine hydrochloride (PHE), tolnaftate 
(TOL), nabumetone (NAB) and tiaprofenic acid (TIA). 
 
4.3. Amlexanox and phenazoparydine hydrochloride induce primary adult 
epithelial cell derived organoid formation  
We next investigated the implications of the candidate drugs amlexanox and 
phenazopyridine hydrochloride, which showed previous specificity for β-catenin 
activation, in lung regeneration, using adult mouse epithelial cells in a 3D organoid 
assay (Figure 4.8.). We tested the increased capability of epithelial progenitor cells 
co-cultured with MLg lung fibroblasts cell line in matrigel to form organoids by two 
different concentrations of each compound, 0.5 and 1 µM, which proved to be 
sufficient to induce Wnt signaling in the Wnt reporter luciferase assay. 
Figure 4.8. Schematic of mouse organoid experimental setup. Primary mouse ATII 




enzymatic dissociation with dispase and MACS sorting of CD45 negative and 
EpCAM positive cells. Cells were seeded in matrigel together with non-proliferative 
MLg lung fibroblasts in well inserts. Media with treatments was changed every 
second to third day. Organoid cultures were maintained for 14 days. Adapted from 
Lehmann et al. (Lehmann et al., 2020). 
 
We observed significant differences in organoid formation between each treatment 
(Figure 4.9.). 
 
Figure 4.9. Representative phase contrast images of whole insert organoids (top) 
and inset images (bottom). Treatments with DMSO, 10 mM LiCl, 0.5 and 1 µM 
amlexanox and 0.5 and 1 µM phenazopyridine hydrochloride started at day 0 and 
continued every 2nd to 3rd day for 14 days. Scale bar=500µm. 
 
Organoid formation capacity was induced by LiCl, amlexanox and lower doses of 




Figure 4.10. Normalized total number of organoids per insert to control (DMSO). 
n=3-14. One sample t-test to a hypothetical value of 1, *p<0.05. Data is presented 
as mean ± SD of independent experiments. Lithium chloride (LiCl), amlexanox 
(AML) and phenazopyridine hydrochloride (PHE). 
 
Interestingly, we saw in parallel that primary adult epithelial cells cultured in 2D 
conditions were more responsive to compound Wnt activation than the MLg lung 
fibroblasts used in the organoid assay (Figures 4.11. and 4.12.). This Wnt 
augmented responsiveness was observed by a non-significant increase in Wnt 
target genes, Axin2 and Lgr5 (Figure 4.11.). 
Figure 4.11. Wnt target gene expression analysis in mouse adult lung epithelial 
cells cultured 2D. a) Axin2 and b) Lgr5. Cells were treated for 24 hours with either 
2 µM of CHIR99021, 0.5 µM of amlexanox (AML) or 0.5 µM of phenazopyridine 
hydrochloride (PHE). n=4-6. Data is presented as mean ± SD of independent 
experiments. One sample t-test to a hypothetical value of 0, *p<0.05. 
 
Wnt induction in MLg mouse lung fibroblasts was only consistently achieved with 









Figure 4.12. Wnt target gene expression analysis in MLg mouse lung fibroblast 
cell line. a) Axin2 and b) Lgr5. Cells were treated for 24h with either 2 µM of 
CHIR99021, 0.5 µM of amlexanox (AML) or 0.5 µM of phenazopyridine 
hydrochloride (PHE). n=4. Data is presented as mean ± SD of independent 
experiments. One sample t-test to a hypothetical value of 0, *p<0.05. 
 
Furthermore, in the organoid cultures, we observed that compound treatment for 
14 days did not alter E-cadherin expression, indicating no disruption of cell to cell 
adhesion which is observed in some cancers where Wnt is dysregulated (Figure 
4.13.). 
Figure 4.13. Maximum intensity projection images of whole mount 
immunofluorescence stainings of day 14 organoids. E-cadherin (red) and DAPI 




Organoids expressed lung epithelial cell markers acetylated alpha tubulin (ACT) 
and pro-surfactant C protein (SFTPC), markers for airway and alveolar epithelial 
cells respectively, as highlighted by the red and green arrows (Figure 4.14.). These 
results show the contribution and importance of progenitor cells to airway as well 
as alveolar lung repair. 
 
Figure 4.14. Images from whole mount immunofluorescent stained day 14 
organoids. Pro-surfactant protein C (SFTPC, green), acetylated alpha tubulin 
(ACT, red) and DAPI (DNA, blue). Scale bar=100µm. Lithium chloride (LiCl), 




4.4. Inhibition of β-catenin reduces amlexanox and phenazopyridine 
hydrochloride organoid formation capacity 
Lung epithelial cell progenitor capability to form organoids in vitro requires Wnt/β-
catenin signaling (Hu et al., 2020). We next determined whether the Wnt pathway 
is functionally required for amlexanox and phenazopyridine hydrochloride to induce 
organoid formation. For this we used another known potent Wnt inhibitor iCRT14, 
which interferes with TCF binding to DNA in addition to influence TCF/β-catenin 
interaction (Gonsalves et al., 2011) (Figure 4.15.). 
 
Figure 4.15. Representative phase contrast images of whole insert day 14 
organoids after 0.5 µM candidate compound treatment amlexanox and 
phenazopyridine hydrochloride with or without 10 µM iCRT14, a potent Wnt 





iCRT14 organoid treatment, significantly reduced organoid numbers when used 
alone or in combination with amlexanox or phenazopyridine hydrochloride (Figure 
4.16.). These data further support the notion that the positive effect of the 




Figure 4.16. Normalized total number of organoids per insert to control (DMSO). 
n=2-14. Data is presented as box plots with median of independent experiments. 
One sample t-test to a hypothetical value of 1, *p<0.05, **p<0.01. Amlexanox 
(AML) and phenazopyridine hydrochloride (PHE). 
 
4.5. Amlexanox treatment improves lung function and induces Wnt related 
genes while reducing disease markers in a mouse model of lung emphysema 
Since amlexanox performed better in the organoid assay than phenazopyridine 
hydrochloride, we selected amlexanox for further investigation. We next 
investigated whether the regenerative effect observed with amlexanox in primary 
adult lung epithelial cell derived organoid cultures could also be observed in vivo 
(Figure 4.17.). We started a daily treatment of amlexanox and induced COPD like 
changes in mouse lungs with elastase orotracheal administration. Animals were 
treated preventively, as performed previously (Kneidinger et al., 2011), with 
vehicle, 25 or 50 mg/kg of amlexanox twice before being challenged with elastase, 





Figure 4.17. Schematic overview of wild type C57BL/6 mice treated with 
amlexanox. Mice were treated preventively either with 25, 50mg/kg of amlexanox 
or vehicle a day before being challenged with 40U/kg of body weight of porcine 
pancreatic elastase and every day for 7 days via oral gavage. Lung function and 
gene expression was analyzed. 
 
Animals treated preventively with 50 mg/kg of amlexanox a day before being 
challenged with elastase and for 7 days, had an improved lung function, and 
translated into a lower lung compliance when compared with mice treated only with 
vehicle or lower dose of amlexanox (Figure 4.18.). 
Figure 4.18. Dynamic compliance from lung function analysis. n=5-15. Data is 
presented as mean ± SD. Mann-Whitney test, *p<0.05, **p<0.01. 
 
Amlexanox in vivo treatment also induced changes in fibroblast growth factor 7 
(Fgf7) and hepatocyte growth factor (Hgf) lung gene expression, which are 
associated with lung repair by promoting distal lung growth and branching of 




Figure 4.19. Lung gene expression analysis of Wnt related genes Fgf7 and Hgf. 
n=9-18. Data is presented as mean ± SD. Mann-Whitney test, *p<0.05, **p<0.01. 
 
ADAM metallopeptidase with thrombospondin type 1 motif 4 (Adamts4) and elastin 
(Eln) lung gene expression, markers associated with COPD (Ezzie et al., 2012; 
Houghton et al., 2006; Uhl et al., 2015) were decreased with amlexanox treatment 
while Mmp12 was increased (Figure 4.20.). 
 
Figure 4.20. Lung gene expression analysis of COPD/emphysema related genes 
Adamts4, Eln and Mmp12. n=9-18. Data is presented as mean ± SD. Mann-










The field of regenerative medicine is evolving rapidly with the growing 
understanding of molecular and cell-specific features during organ development, 
injury and regeneration, provided mainly by stem cell, single cell sequencing and 
cell tracing studies but also by the improvement of experimental models. On the 
other hand, drug development is still a long process, in particular for respiratory 
disease, mainly due to the failure in translating compounds into human application. 
Currently, the importance of rapid drug discovery for finding new treatments for 
emerging respiratory diseases, is being highlighted every day. Drug repurposing 
can shorten the drug development cycle from 10-17 years to 3-12 years and 
represents thus an advantageous approach (Dudley, Deshpande & Butte, 2011). 
Our study provides an early proof of concept for rapid drug translation. Here, we 
propose amlexanox for the treatment of lung emphysema and COPD. We found 
that amlexanox could be used for regenerative pharmacology through Wnt 
signaling activation. 
A first unbiased drug screen, showed that 16 approved compounds induce Wnt 
dependent luciferase activity. Other groups, performing independent cell-based 
screenings, have also reported similar results, which reinforce the reproducibility 
of our findings (Biechele et al., 2010; Zhan et al., 2019; Zhao, Cheng, Theriault, 
Sheridan, Tsai & Haggarty, 2012). Only compounds which showed no promiscuity 
in publicly available bioassays, were further considered in our study. Next, we 
selected five candidate drugs based on a platform for target prediction called 
HitPick. Using HitPick, targets were predicted by molecular comparison of our hits 




which predicted protein targets were found to be associated with either “Wnt” or 
“COPD” or belonging to the GO terms “epithelial cell proliferation” or “regulation of 
inflammatory response” were selected. Our approach goes in line with the 
strategies in place for computational drug repurposing (Dudley, Deshpande & 
Butte, 2011). We have incorporated both drug-based strategies, through chemical 
similarities with other compounds for target prediction, as well as disease-based 
strategies, through the association of the hits’ predicted targets to current 
knowledge of disease and pathology, to select final drug candidates with strong 
potential for COPD treatment. 
We focused our further analysis on amlexanox, phenazopyridine hydrochloride, 
tolnaftate, nabumetone and tiaprofenic acid. All five drugs, induced luciferase 
activity in a confirmatory screening for Wnt induction, using the same cell line we 
used in the initial screen. To exclude the possibility that luciferase increases were 
due to cell proliferation, we measured ATP changes after drug treatment. Wnt is 
associated with cell proliferation, but in our setup we did not observe significant 
increase in number of cells, as demonstrated by cell metabolic activity (Rulifson et 
al., 2007). 
Upon Wnt inhibition, only two compounds showed a significant decrease of their 
Wnt induction capacity in a 2D cell culture. On the one hand, this shows Wnt 
specificity, but on the other hand it could represent a challenge in the disease 
context, where the tissue environment dampens Wnt signaling (Baarsma et al., 
2017). 
Our initial screen was based on results observed in embryonic fibroblasts, so we 




which could not be detected in a 2D and monoculture experimental setup. Both 
amlexanox and phenazopyridine hydrochloride could induce lung organoid 
formation, and led to differentiation of adult epithelial cell, indicating a lung 
regeneration potential. E-cadherin protein expression is essential in maintaining 
epithelial tissue and known to be reduced in many epithelial cell malignancies (Yu, 
Yang, Li & Zhang, 2019). In our hands, amlexanox and phenazopyridine 
hydrochloride did not seem to have a negative effect in e-cadherin expression in 
adult lung epithelial cells. We treated organoid cultures with a Wnt inhibitor and 
saw a significant reduction in organoid formation capacity, accounting for the 
rational of this assay for studying the Wnt pathway. Since amlexanox performed 
better in the 3D assay than phenazopyridine hydrochloride, we moved to the next 
step with amlexanox. 
Our in vivo results indicate that amlexanox treatment could initiate a pro-
regenerative environment in the lung, as observed by an improvement in lung 
function of mice receiving high dose of amlexanox and changes in lung gene 
expression of Fgf7, Hgf, Adamts4 and Eln. FGF7 plays an important role in human 
distal lung growth (Graeff, Wang & McCray, 1999), hepatocyte growth factor (HGF) 
has been demonstrated to be deficient in COPD (Barnes, 2014) and administration 
reversed emphysema in a mouse model (Hegab et al., 2008). In parallel, 
ADAMTS4 and elastin have been shown to be increased in emphysema (Ezzie et 
al., 2012; Houghton et al., 2006). We have shown previously that Wnt activation 
can decrease lung gene expression of MMP12, but to our surprise, Mmp12 was 
increased in mice lungs after amlexanox treatment (Uhl et al., 2015). A possible 
explanation for this observation is the still ongoing inflammation and remodeling 




Amlexanox is used for the treatment of aphthous ulcers, allergic rhinitis and 
asthma. The drug is anti-inflammatory and anti-allergic with immunomodulatory 
properties. The mechanism of action has been described to be through reduction 
of the release of histamine and leukotrienes (Inagaki et al., 1992). Different studies 
indicate that amlexanox administration is associated with weight loss and 
inflammation reduction. Currently, amlexanox is under clinical trial for the treatment 
of type 2 diabetes and obesity (NCT01842282). Amlexanox was shown to have a 
bronchodilator effect in aspirin-induced asthma patients. Therapeutic use of 
leukotrienes in COPD is known to be beneficial. Besides its regenerative potential, 
amlexanox could have an anti-inflammatory effect in COPD. 
Only recently, a study showed that amlexanox can act as a Wnt modulator 
(Bordonaro & Lazarova, 2019). It is important to note that we did not explore the 
mechanism by which amlexanox induces Wnt signaling. 
Furthermore, a recent study characterized stem cell clone libraries of COPD 
patient’s lungs in advanced stages and identified normal lung stem cells present 
and three more predominant pathogenic stem cell variants (Rao et al., 2020). 
These stem cell variants were found to contribute to COPD, and targeting them 
represents an opportunity to treat the disease. This study indicates however that 
COPD patients retain normal lung stem cell niches that could potentially regenerate 
the lung. Discovery of Wnt modulators that selectively affect one or more of these 





6. Conclusion and future directions 
 
In summary, amlexanox was selected as a candidate for the treatment of COPD 
based on a combination of criteria. The use of different phenotypic and 
computational readouts allowed us to select amlexanox as a potential lung repair 
drug (Figure 6.1.). 
 
Figure 6.1. Summary of main strategy and outcomes of this project. 
 
Many other undiscovered uses of drugs exist and finding these new uses is an 
important and necessary step towards reducing disease burden. Our study further 
supports the hypothesis that Wnt/β-catenin signaling is a target for the treatment 
of COPD. The use of amlexanox can lead to activation of regenerative 
mechanisms. Our findings advance drug discovery in the context of lung 




Although Wnt/β-catenin signaling hyper-activity is associated with other diseases, 
temporal and spatial regulation of the pathway is important in determining cellular 
fate (Lehmann et al., 2020). Further studies regarding regenerative potential of the 
adult human lung as well as the regenerative capacity of COPD patient’s lungs are 
needed to understand the true regenerative potential of amlexanox in the lung. 
However, since amlexanox is an approved drug, there is the benefit of knowing 
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